Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Table I [i] PIO pioglitazone, GLP-1R glucagon-like peptide 1 receptor, SGLT2 sodium-glucose co-transporters 2, TOFO tofogliflozin, SUL sulfonylurea, MET metformin, DAPA dapagliflozin, EXE exenatide, NAFLD non-alcoholic fatty liver disease, T2D type 2 diabetes, A1C glycated hemoglobin, ALT alanine aminotransferase, AST aspartate aminotransferase, -GT gamma-glutamyl transferase, MRI-PDFF MRI-proton density fat fraction, MRE-LSM MR elastography-liver stiffness, RCT randomized controlled trial, EDICT Efficacy and Durability of Initial Combination Therapy, CAP controlled attenuation parameter, LSM liver stiffness measurement, BMI body mass index
Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells
T., Miley, G
Alternative medication formats Injectable GLP-1 medications are not the only option
